Compulsory Licensing Laws Revised

BMI View: China's amendment to its pharmaceutical compulsory licensing (CL) regulation is a cause of concern for patent holders, given that the issue of compulsory licences is no longer limited to treatments for infectious diseases. However, given that the country is pushing for the development of innovative products, we believe the approval of any compulsory licences will be counterproductive.

To read the full article, please choose one of the following options: